- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
- Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
- Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
- Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
- Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Appoints Roberto Vieira as President, Oncology
- Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
More ▼
Key statistics
As of last trade Corcept Therapeutics Inc (CORT:NAQ) traded at 22.21, 6.57% above its 52-week low of 20.84, set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 22.47 |
---|---|
High | 22.73 |
Low | 22.00 |
Bid | 21.91 |
Offer | 25.38 |
Previous close | 22.21 |
Average volume | 1.37m |
---|---|
Shares outstanding | 103.84m |
Free float | 91.99m |
P/E (TTM) | 23.28 |
Market cap | 2.31bn USD |
EPS (TTM) | 0.9542 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 21:00 BST.
More ▼